Kymera Therapeutics (NASDAQ:KYMR) Share Price Crosses Below Fifty Day Moving Average – What’s Next?

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s stock price passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $117.58 and traded as low as $114.40. Kymera Therapeutics shares last traded at $115.10, with a volume of 1,278,323 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research note on Thursday, September 10th. Oppenheimer reaffirmed an “outperform” rating and set a $140.00 price target on shares of Kymera Therapeutics in a research report on Thursday, October 29th. Citigroup boosted their price target on Kymera Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a report on Thursday, October 29th. Finally, Wells Fargo & Company raised their price objective on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.16.

Read Our Latest Research Report on Kymera Therapeutics

Kymera Therapeutics Stock Down 3.6%

The company has a market cap of $9.83 billion, a price-to-earnings ratio of -31.80 and a beta of 2.04. The company’s 50-day moving average is $117.58 and its 200 day moving average is $100.51.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The company had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. During the same quarter in the prior year, the company posted ($0.94) earnings per share. The business’s revenue was up .0% on a year-over-year basis. Analysts predict that Kymera Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.

Insider Activity

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the completion of the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $75,855,438.40. The trade was a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 15.98% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently modified their holdings of the business. American Century Companies Inc. raised its holdings in Kymera Therapeutics by 44.5% in the 3rd quarter. American Century Companies Inc. now owns 11,847 shares of the company’s stock valued at $1,324,000 after acquiring an additional 3,651 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $237,000. Algert Global LLC grew its position in shares of Kymera Therapeutics by 530.9% in the third quarter. Algert Global LLC now owns 21,640 shares of the company’s stock valued at $2,419,000 after purchasing an additional 18,210 shares in the last quarter. Castleark Management LLC purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $2,659,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Kymera Therapeutics by 1.8% in the third quarter. Goldman Sachs Group Inc. now owns 1,208,462 shares of the company’s stock valued at $135,094,000 after purchasing an additional 21,129 shares during the last quarter.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs. The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.

Recommended Stories

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.